DEF: eXoZymes Inc. Schedules 2025 Annual Shareholder Meeting, Proposes New Equity Plan and Director Elections

eXoZymes Inc. has announced its 2025 Annual Meeting of Shareholders to be held virtually on July 25, 2025, seeking shareholder approval for director elections, executive compensation, a new performance equity plan, and auditor ratification.

Summary

• The 2025 Annual Meeting of Shareholders for eXoZymes Inc. will be held virtually on July 25, 2025, at 1:00 p.m. Pacific Time.
• Shareholders of record as of June 9, 2025, are entitled to vote, with 8,367,810 common shares outstanding.
• Key proposals include the election of six director nominees, a non-binding advisory vote on named executive officer compensation (say-on-pay), and a non-binding advisory vote on the frequency of future say-on-pay votes (Board recommends every three years).
• The company is seeking approval for the 2025 Performance Equity Plan, which reserves 1,250,000 shares of common stock for awards to employees, consultants, and directors.
• Shareholders will also vote to ratify the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors unanimously recommends a 'FOR' vote on all proposals.
• Total audit fees paid to RBSM LLP were $145,000 in 2024 and $125,000 in 2023.
• Michael Heltzen's compensation was increased on June 17, 2025, to an annualized base salary of $450,000, a one-time bonus of $250,000, and options to purchase 235,817 shares at an exercise price of $12.40 per share.
• As of December 31, 2024, 2,172,445 shares of common stock were committed under the 2020 Equity Incentive Plan, with 424,656 RSUs fully vested and converting to shares on November 11, 2025, and 1,747,789 options issued to key employees.

Sentiment

Score: 7

Explanation: The document outlines a robust corporate governance framework, including independent board committees and a clawback policy, which are positive indicators. The proposed 2025 Performance Equity Plan and increased CEO compensation are designed to incentivize and retain key talent, aligning management interests with long-term shareholder value. While a routine filing, the detailed disclosures and proactive governance measures contribute to a generally positive sentiment regarding the company's operational and strategic stability.

Positives

• The Board of Directors unanimously recommends approval for all proposals, indicating internal alignment.
• The proposed 2025 Performance Equity Plan aims to attract, motivate, and retain high-quality executives, employees, and directors by aligning their interests with shareholder value creation.
• The company has a clear corporate governance structure with independent directors on the Audit, Compensation, and Nominating Committees.
• The adoption of a clawback policy for executive compensation demonstrates a commitment to accountability and financial integrity.
• The increase in CEO Michael Heltzen's compensation and new option grants are designed to incentivize and retain key leadership.

Risks

• The Board of Directors oversees risk management directly and through committees, with the audit committee specifically responsible for major financial risk exposures and cybersecurity risks.
• The company's ability to attract and retain highly qualified executives is dependent on competitive total compensation packages, including equity awards.

Future Outlook

The company's future outlook, as indicated by the proposed 2025 Performance Equity Plan, focuses on attracting and retaining key talent through equity-based incentives to align management and employee interests with long-term shareholder value creation. The plan aims to provide a competitive compensation package to achieve business goals.

Management Comments

• "We cordially invite you to attend the 2025 annual meeting of shareholders..."
• "Our Board recommends a vote: FOR the election of all of the nominees for directors."
• "Our Board recommends a vote: FOR the approval, on a non-binding advisory basis, of the compensation of our named executive officers."
• "Our Board recommends a vote: FOR the proposal, on an advisory basis, approving the frequency of THREE YEARS for holding future advisory votes on executive compensation shareholders vote."
• "Our Board recommends a vote: FOR the proposal to approve the 2025 Performance Equity Plan."
• "Our Board recommends a vote: FOR the ratification of the appointment of RBSM LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025."
• "The Board believes that its overall goal is to award compensation that is reasonable when all elements of potential compensation are considered."
• "The committee believes that cash compensation in the form of base salary and discretionary cash bonuses provides our executives with short-term rewards for success in operations, and that long-term compensation through the award of stock options, restricted stock units and other equity awards aligns the objectives of management with those of our shareholders with respect to long-term performance and success."

Industry Context

The document does not provide specific industry context or trends, focusing primarily on corporate governance, executive compensation, and shareholder proposals for the company's annual meeting. However, the expertise of certain directors in biotechnology, synthetic biology, and protein engineering suggests the company operates within the life sciences or related technology sectors.

Management Changes

Corporate Governance

Related Party Transactions

• As of November 11, 2024, MDB Capital Holdings, LLC (the company's former parent and controlling shareholder) had advanced $4,386,588 to eXoZymes Inc., including undocumented loans totaling $4,136,968 with 5% annual interest.
• Following the initial public offering, eXoZymes Inc. paid $4,243,002 to MDB Capital Holdings, LLC in settlement of the outstanding obligation.
• As of December 31, 2024, a payable of $178,966 remains owed to MDB Capital Holdings, LLC, expected to be paid in 2025 without interest.
• Christopher Marlett and Anthony DiGiandomenico, directors of eXoZymes Inc., are majority shareholders and directors of MDB Capital Holdings, LLC.
• Edgardo Rayo, a director of eXoZymes Inc., is an employee of an affiliate of MDB Capital Holdings, LLC.
• The Audit Committee reviews and approves all related party transactions, considering factors such as ordinary course of business, initiation, terms no less favorable than third-party, purpose, value, and extent of related party interest.

Stakeholder Impact

• Shareholders: Directly impacted by voting on director elections, executive compensation, the new equity plan (potential dilution), and auditor ratification. The virtual meeting format impacts participation.
• Employees/Executives: The 2025 Performance Equity Plan and detailed executive compensation structure, including increased CEO compensation, directly impact their incentives, retention, and potential equity ownership.
• Directors: Subject to re-election, compensation, and corporate governance policies, including indemnification and clawback provisions.
• Auditors (RBSM LLP): Their appointment is subject to shareholder ratification, impacting their ongoing engagement with the company.

Next Steps

• Shareholders are urged to submit their votes promptly via internet, telephone, or mail before the July 24, 2025 deadline.
• The Annual Meeting will be held virtually on July 25, 2025, where preliminary voting results will be announced.
• Final voting results will be disclosed on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting.
• Shareholders wishing to propose actions for the 2026 Annual Meeting must submit proposals by April 2, 2026, for inclusion in the proxy statement, or between April 2, 2026, and May 2, 2026, for advance notice.

Key Dates

Recommendation

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Equity Plan, Director Election, Auditor Ratification, SEC Filing, Shareholder Vote, EXOZ, eXoZymes Inc.